Jean Pierre Boissel

Summary

Country: France

Publications

  1. ncbi request reprint [Therapeutic evaluation and the level proof]
    Jean Pierre Boissel
    Unité pharmaco clinique EZUS APRET, Faculté RTH Laennec, 69376 Lyon 08
    Rev Prat 54:199-206. 2004
  2. ncbi request reprint Pharmacogenetics and responders to a therapy: theoretical background and practical problems
    Jean Pierre Boissel
    Clinical Pharmacology Department, Academic Hospital, Lyon, France
    Clin Chem Lab Med 41:564-72. 2003
  3. doi request reprint Modelling methodology in physiopathology
    Jean Pierre Boissel
    CNRS, UMR5558, Lyon, France
    Prog Biophys Mol Biol 97:28-39. 2008
  4. ncbi request reprint [New approaches in pharmacology: numerical modelling and simulation]
    Jean Pierre Boissel
    Service de Pharmacologie Clinique, Faculté RTH Laënnec et Hôpital Cardiologique, Lyon, France
    Therapie 60:1-15. 2005
  5. ncbi request reprint Bridging the gap between therapeutic research results and physician prescribing decisions: knowledge transfer, a prerequisite to knowledge translation
    Jean Pierre Boissel
    Faculté RTH Laennec, Service de Pharmacologie Clinique EA3736, Rue Guillaume Paradin, 69376, Lyon Cedex 08, France
    Eur J Clin Pharmacol 60:609-16. 2004
  6. doi request reprint New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linear
    Jean Pierre Boissel
    Institute for Theoretical Medicine and CNRS UMR5558, RTH Laennec School of Medicine, Rue Guillaume Paradin, 69008 Lyon, France
    J Clin Epidemiol 61:301-7. 2008
  7. ncbi request reprint Planning of clinical trials
    J P Boissel
    Clinical Pharmacology Department, RTH Laennec School of Medicine, Lyon Cedex, France
    J Intern Med 255:427-38. 2004
  8. ncbi request reprint Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor compliance
    Jean Pierre Boissel
    Department of Clinical Pharmacology, Claude Bernard University and Teaching Hospital, Lyon, France
    Clin Pharmacokinet 41:1-6. 2002
  9. ncbi request reprint How to measure non-consistency of medical practices with available evidence in therapeutics: a methodological framework
    Jean Pierre Boissel
    Centre de Recherche en Ingénierie des Connaissances Appliquée à la Thérapeutique Service de Pharmacologie Clinique EA3637, Faculté de médecine RTH Laennec, Universite Claude Bernard, Lyon, Cedex 08, France
    Fundam Clin Pharmacol 19:591-6. 2005
  10. ncbi request reprint Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments
    Jean Pierre Boissel
    Service de Pharmacologie Clinique, Claude Bernard University, Faculté RTH Laennec, Rue G Paradin, 69376 Lyon, France
    Fundam Clin Pharmacol 19:579-84. 2005

Collaborators

Detail Information

Publications46

  1. ncbi request reprint [Therapeutic evaluation and the level proof]
    Jean Pierre Boissel
    Unité pharmaco clinique EZUS APRET, Faculté RTH Laennec, 69376 Lyon 08
    Rev Prat 54:199-206. 2004
  2. ncbi request reprint Pharmacogenetics and responders to a therapy: theoretical background and practical problems
    Jean Pierre Boissel
    Clinical Pharmacology Department, Academic Hospital, Lyon, France
    Clin Chem Lab Med 41:564-72. 2003
    ..No method is currently both fully adequate and validated. Finally, the predictive models, which we need to identify responders, do not exist in practice. Fortunately, new research approaches have been developed recently...
  3. doi request reprint Modelling methodology in physiopathology
    Jean Pierre Boissel
    CNRS, UMR5558, Lyon, France
    Prog Biophys Mol Biol 97:28-39. 2008
    ..Tools and techniques for integrating the parameter range of experimental values, level of evidence and missing data are needed...
  4. ncbi request reprint [New approaches in pharmacology: numerical modelling and simulation]
    Jean Pierre Boissel
    Service de Pharmacologie Clinique, Faculté RTH Laënnec et Hôpital Cardiologique, Lyon, France
    Therapie 60:1-15. 2005
    ..Such approaches are considered in drug innovation and development. They require a multidisciplinary approach, and this will involve modification of the way research in pharmacology is conducted...
  5. ncbi request reprint Bridging the gap between therapeutic research results and physician prescribing decisions: knowledge transfer, a prerequisite to knowledge translation
    Jean Pierre Boissel
    Faculté RTH Laennec, Service de Pharmacologie Clinique EA3736, Rue Guillaume Paradin, 69376, Lyon Cedex 08, France
    Eur J Clin Pharmacol 60:609-16. 2004
    ....
  6. doi request reprint New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linear
    Jean Pierre Boissel
    Institute for Theoretical Medicine and CNRS UMR5558, RTH Laennec School of Medicine, Rue Guillaume Paradin, 69008 Lyon, France
    J Clin Epidemiol 61:301-7. 2008
    ..We have called this relation the effect model. Our objectives were to demonstrate that the relation is general and not necessarily linear...
  7. ncbi request reprint Planning of clinical trials
    J P Boissel
    Clinical Pharmacology Department, RTH Laennec School of Medicine, Lyon Cedex, France
    J Intern Med 255:427-38. 2004
    ..As such, it should meet the fundamentals of scientific discovery that guarantee causality between the observed difference and the intervention. All the planning components are thought according to these fundamentals...
  8. ncbi request reprint Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor compliance
    Jean Pierre Boissel
    Department of Clinical Pharmacology, Claude Bernard University and Teaching Hospital, Lyon, France
    Clin Pharmacokinet 41:1-6. 2002
    ..A marker of forgiveness would be of some help for doctors deciding which drug to prescribe to patients who are poor compliers...
  9. ncbi request reprint How to measure non-consistency of medical practices with available evidence in therapeutics: a methodological framework
    Jean Pierre Boissel
    Centre de Recherche en Ingénierie des Connaissances Appliquée à la Thérapeutique Service de Pharmacologie Clinique EA3637, Faculté de médecine RTH Laennec, Universite Claude Bernard, Lyon, Cedex 08, France
    Fundam Clin Pharmacol 19:591-6. 2005
    ..All these features should be taken into account for a more accurate and relevant assessment of the distance...
  10. ncbi request reprint Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments
    Jean Pierre Boissel
    Service de Pharmacologie Clinique, Claude Bernard University, Faculté RTH Laennec, Rue G Paradin, 69376 Lyon, France
    Fundam Clin Pharmacol 19:579-84. 2005
    ..This result suggests that the apparent effect on blood pressure is not the only cause of stroke risk reduction in hypertensive subjects submitted to an antihypertensive medicine...
  11. ncbi request reprint A modelling approach to explore some hypotheses of the failure of neuroprotective trials in ischemic stroke patients
    Marie Aimée Dronne
    Universite de Lyon, Lyon, F 69003, France
    Prog Biophys Mol Biol 97:60-78. 2008
    ..It reinforces the hypothesis that histological and morphological differences between rodent and human brains can partly explain the failure of these agents in clinical trials...
  12. ncbi request reprint Mathematical modelling of an ischemic stroke: an integrative approach
    Marie Aimée Dronne
    Service de Pharmacologie Clinique, EA 643, Faculte de Medecine Laennec, Universite Claude Bernard, Lyon, France
    Acta Biotheor 52:255-72. 2004
    ....
  13. pmc Treatment of high blood pressure and gain in event-free life expectancy
    Behrouz Kassai
    Department of Clinical Pharmacology, Claude Bernard University, Lyon, France
    Vasc Health Risk Manag 1:163-9. 2005
    ..Consideration of absolute risk has been recommended for making decisions concerning preventive treatment in hypertension. We performed simulations to estimate the benefit of antihypertensive therapy over a life-time...
  14. ncbi request reprint Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris
    Sylvie Chabaud
    Service de Pharmacologie Clinique, Faculté RTH Laennec, Rue Guillaume Paradin, BP 8071, 69376 Lyon, France
    J Pharmacokinet Pharmacodyn 29:339-63. 2002
    ....
  15. ncbi request reprint Role of astrocytes in grey matter during stroke: a modelling approach
    Marie Aimée Dronne
    UMR 5558, Université Lyon1, CNRS, Institut de Médecine Théorique, Lyon, France
    Brain Res 1138:231-42. 2007
    ..A detailed understanding of astrocytic function and influence on neuron survival during stroke is necessary to improve the neuroprotective strategies for stroke patients...
  16. pmc The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests
    Behrouz Kassai
    Department of Clinical Pharmacology EA 3736, University Hospital of Lyon, Rue Guillaume Paradin, BP 8071, Lyon cedex 08 69376, France
    J Clin Epidemiol 58:1042-51. 2005
    ..by the reference standard a valid surrogate? (2) How does the tests accuracy influence the estimate of the treatment benefit on surrogate? (3) Is it possible to correct the measured treatment effect given by results of inaccurate tests?..
  17. ncbi request reprint Compliance-guided therapy : a new insight into the potential role of clinical pharmacologists
    Alexia Blesius
    Clinical Pharmacology Department, Cardiovascular Hospital, Lyon 69003, France
    Clin Pharmacokinet 45:95-104. 2006
    ..The example considered is that of oral anticoagulant treatment prescribed long-term...
  18. pmc Literature search parameters marginally improved the pooled estimate accuracy for ultrasound in detecting deep venous thrombosis
    Behrouz Kassai
    Clinical Investigation Centre INSERM, Department of Clinical Pharmacology EA 3736, Hôpitaux de Lyon, Universite Claude Bernard Lyon I, Lyon Cedex 08, France
    J Clin Epidemiol 59:710-4. 2006
    ..Our objectives were to compare search strategies with and without methodological terms in Medline, to find out how other databases complement Medline, and how these strategies affect the pooled estimates of the accuracy...
  19. ncbi request reprint Getting evidence to prescribers and patients or how to make EBM a reality
    Jean Pierre Boissel
    Service de Pharmacologie Clinique EA643, Faculté RTH Laennec, Lyon, France
    Stud Health Technol Inform 95:554-9. 2003
    ..We conceived a new paradigm and designed an Internet process based on it by which unbiased evidence is brought to doctors in such a format that it can be accessed and used during the visit...
  20. doi request reprint Revisiting the level of evidence in randomized controlled clinical trials: A simulation approach
    Agathe Bajard
    Universite Lyon 1, Léon Bérard Anticancer Centre, Department of Public Health, Biostatistics and Therapeutic evaluation Unit, Lyon, France
    Contemp Clin Trials 30:400-10. 2009
    ..However, evaluating available evidence is often still based on intuitive processes rather than on rigorous scientific analysis...
  21. ncbi request reprint A mathematical model of ion movements in grey matter during a stroke
    Marie Aimée Dronne
    Service de Pharmacologie Clinique, EA 3736, Faculte de Medecine Laennec, Rue Guillaume Paradin, BP 8071, 69376 Lyon, Cedex 08, France
    J Theor Biol 240:599-615. 2006
    ..This approach may help to explore new therapeutic strategies in order to reduce stroke damage...
  22. doi request reprint SCORE should be preferred to Framingham to predict cardiovascular death in French population
    Ivanny Marchant
    IMTh Institute for Theoretical Medicine CNRS, UMR 5558, Laboratoire de Biometrie et Biologie Evolutive, Service de Pharmacologie Clinique, Lyon, France
    Eur J Cardiovasc Prev Rehabil 16:609-15. 2009
    ..Numerous studies have examined the validity of available scores to predict the absolute cardiovascular risk...
  23. pmc A systematic review of the accuracy of ultrasound in the diagnosis of deep venous thrombosis in asymptomatic patients
    Behrouz Kassai
    Clinical Pharmacology Unit, Rue Guillaume Paradin BP8071 69376, Lyon Cedex 08, France
    Thromb Haemost 91:655-66. 2004
    ..Our results suggest that, particularly for proximal veins, ultrasound is accurate for the diagnosis of DVT in asymptomatic postoperative orthopedic patients. More research is needed in other clinical settings...
  24. ncbi request reprint Use of sensitivity functions to characterise and compare the forgiveness of drugs
    Patrice Nony
    Clinical Pharmacology Unit, EA 643, Cardiovascular Hospital, Lyon, France
    Clin Pharmacokinet 41:371-80. 2002
    ....
  25. ncbi request reprint Physiologically based model of acute ischemic stroke
    Vincent Duval
    Department of Clinical Pharmacology, EA643, School of Medicine, Universite Claude Bernard, Lyon, France
    J Cereb Blood Flow Metab 22:1010-8. 2002
    ..The model integrated different markers of acute ischemic stroke into a single entity in order to mimic acute ischemic stroke, and has been shown to have a reasonable degree of internal validity...
  26. doi request reprint A pharmacologically based multiscale mathematical model of angiogenesis and its use in investigating the efficacy of a new cancer treatment strategy
    Frédérique Billy
    Universite de Lyon, F 69000 Lyon, France
    J Theor Biol 260:545-62. 2009
    ..This theoretical model may be useful to evaluate the efficacy of therapies targeting angiogenesis, and could therefore contribute to designing prospective clinical trials...
  27. doi request reprint Exploration of beneficial and deleterious effects of inflammation in stroke: dynamics of inflammation cells
    Taïssia Lelekov-Boissard
    Faculte de Medecine Laennec, Universite Claude Bernard Lyon 1, 69372 Lyon Cedex 08, France
    Philos Transact A Math Phys Eng Sci 367:4699-716. 2009
    ..This approach may help to explore the respective contributions of the beneficial and deleterious roles of the inflammatory process in stroke, and to study various therapeutic strategies in order to reduce stroke damage...
  28. pmc Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials
    Rémy Boussageon
    Department of General Medicine, Universite Claude Bernard Lyon 1, Lyon, France
    PLoS Med 9:e1001204. 2012
    ..Since then, it has been the first-line treatment in overweight patients with type 2 diabetes. However, metformin-sulphonylurea bitherapy may increase mortality...
  29. ncbi request reprint New tools to measure discrepancy between prescribing practices and guideline recommendations
    Catherine Mercier
    Service de Biostatistique, Hospices Civils de Lyon, Lyon, France
    J Eval Clin Pract 13:639-46. 2007
    ..To study the performance of a new method designed to measure discrepancy between real prescriptions and evidence-based reference treatments...
  30. ncbi request reprint Level of evidence and therapeutic evaluation: need for more thoughts
    Nadine Bossard
    Service de Biostatistique, Centre Hospitalier Lyon Sud, Lyon, France
    Fundam Clin Pharmacol 18:365-72. 2004
    ....
  31. ncbi request reprint Bioequivalence evaluation of a fixed combination of chloroquine and proguanil in a capsule formulation versus a standard medication
    Jean François Chaulet
    Laboratoire de Biochimie Toxicologie et Pharmacologie de l Hôpital d Instruction des Armées Desgenettes, Lyon, France
    Arzneimittelforschung 52:407-12. 2002
    ..Therefore, the use of a single capsule instead of one chloroquine tablet and two proguanil tablets daily can be proposed in order to increase the prophylactic compliance without decreasing the prophylactic efficacy...
  32. ncbi request reprint Why don't cancer patients enter clinical trials? A review
    Patrick Castel
    ONCORA, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Eur J Cancer 42:1744-8. 2006
    ....
  33. ncbi request reprint A simple tool to evoke physicians' real training needs
    David Perol
    Department of Public Health, Leon Berard Center, Lyon, France
    Acad Med 77:407-10. 2002
    ..However, it should be assessed further by those involved in CME for general practitioners...
  34. pmc Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods
    Jean Sebastien Hulot
    Pharmacology Department, Pitie Salpetriere Hospital, Paris, France, Clinical Pharmacology Unit, Lyon Hospitals, Lyons, France
    Br J Clin Pharmacol 55:299-306. 2003
    ..This study was conducted to compare the efficiency of two interim analysis procedures, which could be used to allow early termination of a clinical trial...
  35. ncbi request reprint J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data
    Florent Boutitie
    Claude Bernard University, Lyon, France
    Ann Intern Med 136:438-48. 2002
    ..However, several studies in hypertensive patients receiving treatment have described this relationship as J-shaped, with an increased risk for events in patients with low blood pressure...
  36. ncbi request reprint Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups
    Jerzy Gasowski
    Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Herestraat 49, B 3000 Leuven, Belgium
    J Hypertens 20:145-51. 2002
    ..This study explored the independent roles of pulse pressure and mean pressure as predictors of mortality in a wide range of patients with hypertension...
  37. ncbi request reprint How should therapeutic information be transferred to users?
    Jean Pierre Boissel
    EA 643 Clinical Pharmacology Department, RTH Leannec School of Medicine, Claude Bernard University, Rue Guillaume Paradin 69376 Lyon Cedex 08, France
    Fundam Clin Pharmacol 17:495-503. 2003
    ..We suggest that a new approach is possible by reducing the transferred information to its core and integrating it through appropriate representation models into the doctor's decision-making process...
  38. ncbi request reprint Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit?
    Behrouz Kassai
    EA 643 Clinical Pharmacology Unit, Claude Bernard University, Facultá RTH Laennec, Rue Guillaume Paradin BP 8071 69376, Lyon 08, France
    J Clin Epidemiol 56:977-82. 2003
    ..Considering the gain in event-free life expectancy, low-risk patients benefit more than high-risk patients do, at the expense of a longer treatment exposure. The interpretation of the AB changes depending on follow-up...
  39. ncbi request reprint How to deal with multiple treatment or dose groups in randomized clinical trials? Another approach
    Jean Pierre Boissel
    Fundam Clin Pharmacol 21:155-6. 2007
    ..It is better to avoid it by careful thinking prior to beginning the experiment. In fundamental and clinical pharmacology, there are several established concepts that allow researchers to minimize the cases where the issue arises...
  40. ncbi request reprint Risk reduction for stroke and coronary events
    Jean Pierre Boissel
    Lancet 359:1249; author reply 1250-1. 2002
  41. ncbi request reprint QxDB: a generic database to support mathematical modelling in biology
    Benjamin Ribba
    Institute for Theoretical Medicine and Clinical Pharmacology Department, Faculty of Medicine RTH Laennec, University of Lyon, Paradin St, POB 8071, 69376 Lyon Cedex 08, France
    Philos Transact A Math Phys Eng Sci 364:1517-32. 2006
    ..We will illustrate this adaptability of QxDB by presenting two examples, the first dealing with modelling in oncology and the second with mechanical properties of cells and tissues...
  42. ncbi request reprint Evaluation of two evidence-based knowledge transfer interventions for physicians. A cluster randomized controlled factorial design trial: the CardioDAS Study
    Emmanuel Amsallem
    Service de Pharmacologie Clinique UMR CNRS 5558, Hopital Cardiologique, 69003 Lyon, France
    Fundam Clin Pharmacol 21:631-41. 2007
    ..Passive' transfer seems far less efficient. In addition, the size of the benefit remains small and its consequences limited in practice...
  43. ncbi request reprint [Meta-analysis of clinical trials: uses and pitfalls]
    Jean Pierre Boissel
    RTH, Laennec, Lyon 1
    Bull Acad Natl Med 191:759-70. 2007
    ..Meta-analysis of clinical trials allows all available quantitative evidence on therapeutic efficacy, to be condensed. Critical appraisal of all available evidence is a pillar of clinical science...
  44. doi request reprint How to anticipate the assessment of the public health benefit of new medicines?
    Jacques Massol
    Phisquare Institute, The Foundation Transplantation, Besancon, France
    Therapie 62:427-35. 2007
    ..Finally, because of the PHB's universal dimension, it is suggested that the necessary actions and publications be initiated so that the PHB can be acknowledged at the European level...
  45. ncbi request reprint Soluble Fas ligand and atherosclerosis in hypertensive patients
    Jean Pierre Boissel
    J Hypertens 20:819-20. 2002
  46. doi request reprint [How should one anticipate the assessment of the public health benefit of new medicines?]
    Jacques Massol
    Institut Phisquare, Fondation Transplantation, Besancon, France
    Therapie 62:417-25. 2007